565 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
by the aforementioned Captisol equipment accelerated depreciation, a one-time stock compensation expense and a $24.8 million deferred tax asset … primarily to the aforementioned Captisol equipment accelerated depreciation in 2022, a one-time stock compensation expense and a $24.8 million deferred tax
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit … from share-based compensation, income tax affect of adjusted reconciling items and others that are listed in the itemized reconciliations between GAAP
8-K/A
0pj9 8sup
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
qae5gova8efqbfxz 1j
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
y9zfos
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
me92fqspt e5im
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
rbztblm ts2
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
23jzqyx
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
8-K
EX-99.1
s5o0zr4t24mwtkp
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
8-K
2pf2u ovzktd
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm